Johnson & Johnson Receivables 2010-2024 | JNJ
Johnson & Johnson receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
- Johnson & Johnson receivables for the quarter ending September 30, 2024 were $16.174B, a 9.3% increase year-over-year.
- Johnson & Johnson receivables for 2023 were $14.873B, a 5.94% increase from 2022.
- Johnson & Johnson receivables for 2022 were $14.039B, a 8.14% decline from 2021.
- Johnson & Johnson receivables for 2021 were $15.283B, a 12.57% increase from 2020.
Johnson & Johnson Annual Receivables
(Millions of US $) |
| 2023 |
$14,873 |
| 2022 |
$14,039 |
| 2021 |
$15,283 |
| 2020 |
$13,576 |
| 2019 |
$14,481 |
| 2018 |
$14,098 |
| 2017 |
$13,490 |
| 2016 |
$11,699 |
| 2015 |
$10,734 |
| 2014 |
$10,985 |
| 2013 |
$11,713 |
| 2012 |
$11,309 |
| 2011 |
$10,581 |
| 2010 |
$9,774 |
| 2009 |
$9,646 |
Johnson & Johnson Quarterly Receivables
(Millions of US $) |
| 2024-09-30 |
$16,174 |
| 2024-06-30 |
$15,794 |
| 2024-03-31 |
$14,946 |
| 2023-12-31 |
$14,873 |
| 2023-09-30 |
$14,798 |
| 2023-06-30 |
$16,777 |
| 2023-03-31 |
$16,350 |
| 2022-12-31 |
$14,039 |
| 2022-09-30 |
$15,890 |
| 2022-06-30 |
$16,139 |
| 2022-03-31 |
$15,594 |
| 2021-12-31 |
$15,283 |
| 2021-09-30 |
$14,911 |
| 2021-06-30 |
$14,871 |
| 2021-03-31 |
$14,938 |
| 2020-12-31 |
$13,576 |
| 2020-09-30 |
$14,579 |
| 2020-06-30 |
$14,645 |
| 2020-03-31 |
$14,874 |
| 2019-12-31 |
$14,481 |
| 2019-09-30 |
$14,801 |
| 2019-06-30 |
$14,653 |
| 2019-03-31 |
$14,115 |
| 2018-12-31 |
$14,098 |
| 2018-09-30 |
$14,048 |
| 2018-06-30 |
$14,111 |
| 2018-03-31 |
$14,166 |
| 2017-12-31 |
$13,490 |
| 2017-09-30 |
$13,155 |
| 2017-06-30 |
$13,283 |
| 2017-03-31 |
$12,300 |
| 2016-12-31 |
$11,699 |
| 2016-09-30 |
$11,798 |
| 2016-06-30 |
$12,062 |
| 2016-03-31 |
$11,406 |
| 2015-12-31 |
$10,734 |
| 2015-09-30 |
$11,366 |
| 2015-06-30 |
$11,968 |
| 2015-03-31 |
$11,533 |
| 2014-12-31 |
$10,985 |
| 2014-09-30 |
$11,615 |
| 2014-06-30 |
$12,257 |
| 2014-03-31 |
$12,116 |
| 2013-12-31 |
$11,713 |
| 2013-09-30 |
$12,027 |
| 2013-06-30 |
$11,614 |
| 2013-03-31 |
$11,515 |
| 2012-12-31 |
$11,309 |
| 2012-09-30 |
$11,175 |
| 2012-06-30 |
$10,992 |
| 2012-03-31 |
$10,982 |
| 2011-12-31 |
$10,581 |
| 2011-09-30 |
$10,552 |
| 2011-06-30 |
$10,982 |
| 2011-03-31 |
$10,861 |
| 2010-12-31 |
$9,774 |
| 2010-09-30 |
$10,290 |
| 2010-06-30 |
$9,629 |
| 2010-03-31 |
$10,018 |
| 2009-12-31 |
$9,646 |
| 2009-09-30 |
$10,279 |
| 2009-06-30 |
$10,133 |
| 2009-03-31 |
$9,831 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
